Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126481311 | 12648131 | 1 | I | 20160805 | 20160812 | 20160812 | EXP | PT-SA-2016SA144755 | AVENTIS | 48.00 | YR | A | M | Y | 0.00000 | 20160812 | MD | PT | PT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126481311 | 12648131 | 1 | PS | RIFAMPICIN | RIFAMPIN | 1 | Unknown | UNK | 50627 | ||||||||||
| 126481311 | 12648131 | 2 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-4/2 | U | UNK | 0 | 50 | MG | QD | |||||
| 126481311 | 12648131 | 3 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-4/2 | U | UNK | 0 | 62.5 | MG | QD | |||||
| 126481311 | 12648131 | 4 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-4/2 | U | UNK | 0 | 75 | MG | QD | |||||
| 126481311 | 12648131 | 5 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-2/1 | U | UNK | 0 | 50 | MG | QD | |||||
| 126481311 | 12648131 | 6 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-4/2 | U | UNK | 0 | 37.5 | MG | QD | |||||
| 126481311 | 12648131 | 7 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-4/2 | U | UNK | 0 | 50 | MG | QD | |||||
| 126481311 | 12648131 | 8 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-2/1 | U | UNK | 0 | 50 | MG | QD | |||||
| 126481311 | 12648131 | 9 | SS | SUNITINIB MALATE. | SUNITINIB MALATE | 1 | Unknown | SCHEME-2/1 | U | 0 | 75 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126481311 | 12648131 | 1 | Tuberculosis of genitourinary system |
| 126481311 | 12648131 | 2 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 3 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 4 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 5 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 6 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 7 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 8 | Metastatic renal cell carcinoma |
| 126481311 | 12648131 | 9 | Metastatic renal cell carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126481311 | 12648131 | HO |
| 126481311 | 12648131 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126481311 | 12648131 | Drug interaction | |
| 126481311 | 12648131 | Rash | |
| 126481311 | 12648131 | Stomatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126481311 | 12648131 | 7 | 201605 | 0 |